Long-term safety and tolerability of entecavir in patients with chronic hepatitis B in the rollover study ETV-901

Michael P. Manns, Ulus S. Akarca, Ting Tsung Chang, William Sievert, Seung Kew Yoon, Naoky Tsai, Albert Min, Andreas Pangerl, Suzanne Beebe, Miao Yu, Suchat Wongcharatrawee

研究成果: Article

42 引文 斯高帕斯(Scopus)

摘要

Objective: To review long-term safety data from the rollover study ETV-901, focusing on adverse events (AEs) with a potential nucleos(t)ide association. Methods: The open-label study ETV-901 (AI463901) assessed the safety of entecavir in chronic hepatitis B patients who received entecavir, lamivudine or adefovir monotherapy in previous entecavir Phase II/III studies. Long-term cumulative safety results are based on reported AEs, regardless of causal relationship. Results: Median exposure to entecavir in study ETV-901 was 184 weeks. Commonly reported AEs (≥ 10%) were upper respiratory tract infection, headache and nasopharyngitis. Most AEs were mild to moderate; 203 (19%) patients reported grade 3 4 AEs, with 45 (4%) considered related to entecavir. There were 14 (1%) discontinuations due to AEs. On-treatment alanine aminotransferase (ALT) flares were reported in 32 (3%) patients and were associated with a reduction in hepatitis B virus DNA of more than 2 log10 copies/ml in 25/32 patients. AEs potentially associated with nucleos(t)ide analogs were infrequent, the most common being myalgia (n = 54; 5%) and neuropathy-related AEs (hypoparesthesia and hyperparesthesia, polyneuropathy; n = 42; 4%). Conclusions: Long-term administration of entecavir was associated with low rates of serious AEs, discontinuations due to AEs and ALT flares. AEs potentially associated with nucleos(t)ide use occurred at low rates.

原文English
頁(從 - 到)361-368
頁數8
期刊Expert Opinion on Drug Safety
11
發行號3
DOIs
出版狀態Published - 2012 五月 1

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)

指紋 深入研究「Long-term safety and tolerability of entecavir in patients with chronic hepatitis B in the rollover study ETV-901」主題。共同形成了獨特的指紋。

  • 引用此

    Manns, M. P., Akarca, U. S., Chang, T. T., Sievert, W., Yoon, S. K., Tsai, N., Min, A., Pangerl, A., Beebe, S., Yu, M., & Wongcharatrawee, S. (2012). Long-term safety and tolerability of entecavir in patients with chronic hepatitis B in the rollover study ETV-901. Expert Opinion on Drug Safety, 11(3), 361-368. https://doi.org/10.1517/14740338.2012.653340